The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
D Falke - One of the best experts on this subject based on the ideXlab platform.
-
mixed vaginal infections of balb c mice with low virulent herpes simplex type 1 strains result in restoration of virulence properties vaginitis Vulvitis and neuroinvasiveness
Medical Microbiology and Immunology, 1997Co-Authors: Mark W Lingen, F Hengerer, D FalkeAbstract:Vaginal infections of BALB/c Ann mice with herpes simplex virus type 1 (HSV-1) were studied. Mice were inoculated with virulent strains ANG path and 17 syn+ or low-virulent recombinant strains 27/III and 17-syn3 that differ from parental strains in their glycoprotein B (gB) gene sequences. When low-virulent strains were inoculated separately, no vaginitis/Vulvitis was produced despite replication in the vagina. In contrast, after coinfection of mice with the two low-virulent strains, vaginitis/Vulvitis was produced and virus could be recovered from the central nervous system (CNS). Two of the CNS isolates produced vaginitis/Vulvitis, neuroinvasiveness and death of mice after vaginal infection. Restriction fragment analysis and sequencing were used to assess recombination events in the gB gene sequence of the CNS isolates. After mixed vaginal infection recombination between non-virulent HSV strains occurs, resulting in vaginitis/Vulvitis and neuroinvasiveness. No correlation was detected between the syncytial phenotype and local vaginal virulence. Virulence of HSV is not solely dependent on gB function; it seems to be more probable that several genes act in concert to induce virulence and neuroivasiveness.
-
pathogenesis of hsv 1 2 induced vaginitis Vulvitis of the mouse dependence of lesions on genetic properties of the virus and analysis of pathohistology
Archives of Virology, 1993Co-Authors: M Fleck, Jurgen Podlech, K Weise, H Muntefering, D FalkeAbstract:A scoring system for herpes simplex virus (HSV) induced vaginitis/Vulvitis in Balb/c mice was delineated from vaginal infections. Four degrees of vaginitis/Vulvitis could be distinguished after infection with suitable strains of HSV despite nearly identical replication rates. The time course of replication, inflammation and pathohistology was compared further. Grade 0 was defined by lack of symptoms despite presence of strong replication, which was detectable at days 3-6. Focal necrotic lesions of the epithelial layer were present containing HSV-specific antigens. DNA could be detected by hybridization only in the outer zone of these areas. At day 6 these zones began to be re-epithelialized. In the vaginal lumen abundant detached epithelial cells and granulocytes were already present by day 2. Grade 1 was macroscopically characterized by a slight inflammation commencing on days 5-6. Replication and antigens in the epithelium were found on days 2-6. HSV-antigens were only detected above the basal membrane, and some infiltration with granulocytes and lymphocytes was observed below the basal membrane at day 4. Grade 2 showed strong redness and inflammation as well as hyperemia. Cellular infiltrates were present in the large antigen containing epithelial lesions and below the basal membrane. From day 4 on, neurons were HSV-antigen and DNA positive and macrophages in the stroma contained antigen. The vulva was also shown to be involved. Grade 3 exhibited prolonged severe hyperemia, and destruction of the epithelium and the stroma with necrosis and infiltration, especially of the vulva. This grading system was shown to depend on certain unknown genetic properties of HSV-strains. Neither thymidine-kinase activity, replication in macrophages, fusion activity of strains nor presence or absence of the Hpa I P-fragment were shown to be of importance for severity of vaginitis/Vulvitis. Vaginitis/Vulvitis was shown to be an all or none response to HSV independent of the rate of replication. The set of virus genes responsible for neuroinvasiveness after vaginal or i.p. inoculation was found to be different. The time course of replication (mainly days 3-6) and inflammation (days 5-10) indicates that inflammation seems to be a secondary immunological phenomenon induced later by the replication phase of HSV. Our system could be useful for separately testing drugs with antiviral and anti-inflammatory properties.
Roger P Goldberg - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of zoon s Vulvitis with high potency topical steroid
International Urogynecology Journal, 2006Co-Authors: Sylvia M Botros, Mark Dieterich, Peter K Sand, Roger P GoldbergAbstract:Zoon’s Vulvitis is a rare, chronic condition of the vulva that presents with burning, pruritus, and dysuria with characteristic lesions and histopathology. Several treatment options have been reported with limited success. A 63-year-old woman with Zoon’s Vulvitis diagnosed on histopathology was treated with clobetasol propionate 0.05%. Complete resolution of her symptoms and lesions occurred in less than 1 week. No recurrence of her symptoms has occurred after 9 months. Zoon’s Vulvitis may be successfully and expeditiously treated with high potency topical steroids.
Monica Corazza - One of the best experts on this subject based on the ideXlab platform.
-
comparative study on topical immunomodulatory and anti inflammatory treatments for plasma cell Vulvitis long term efficacy and safety
Journal of The European Academy of Dermatology and Venereology, 2015Co-Authors: Annarosa Virgili, Sara Minghetti, Alessandro Borghi, Monica CorazzaAbstract:Background Evidence on the treatment of plasma cell Vulvitis (PCV) is scarce and comparative studies are lacking. Objective To assess and compare the effectiveness and safety, on a long-term basis, of three topical interventions for the treatment of PCV. Methods Retrospectively collected efficacy and safety data of a cohort of PCV patients treated with fusidic acid 2% and betamethasone valerate 0.1% cream fixed combination (FA/BM, 14 patients), clobetasol propionate 0.05% ointment (CP, six patients) and tacrolimus 0.1% ointment (TC, four patients) at different regimens between January 2000 and June 2013 were analysed. Treatment outcome was assessed according to Investigator Global Assessment (i) symptoms and (ii) signs, at 12, 24 and 52 weeks. Results After 12 weeks, 85% of all patients achieved satisfactory improvement in PCV-related symptoms and maintained the improvement across a 52-week observation period. About 45% achieved a satisfactory result in clinical signs after 12 weeks, without further improvement during the following 9 months. No statistical differences in response were found among treatment groups at 12, 24 and 52 weeks. All study treatments were significantly more effective in improving PCV symptoms rather than clinical signs. With regard to treatment tolerability, one patient (7.1%) in FA/BM group and one (25%) in TC group discontinued the treatment due to local side-effects. Conclusions CP, FA/BM and TC are effective and safe in treating PCV, inducing both a rapid improvement of the disease, notably of symptoms, and stabilizing its control.
-
symptoms in plasma cell Vulvitis first observational cohort study on type frequency and severity
Dermatology, 2015Co-Authors: Annarosa Virgili, Monica Corazza, Sara Minghetti, Alessandro BorghiAbstract:Background: Studies assessing symptoms of plasma cell Vulvitis (PCV) are lacking. Objectives: To assess the prevalence and severity of PCV-related symptoms and identify possible associations between patient characteristics, clinical features of PCV and treatments administered before a definitive diagnosis. Methods: Thirty-six patients affected with PCV were included. Data were collected by direct interview and clinical examination. Results: Thirty patients (83.3%) complained of symptoms: burning was the most frequent (80.6%) while dyspareunia was the severest. Of the symptomatic patients, 73.3% experienced severe symptoms. Severity of symptoms was not associated with age at onset and duration of PCV. Almost 70% of the patients had previously undergone treatments. Conclusions: Symptoms in PCV are frequent and more than often severe. Neither age at onset nor duration of the disease nor the extent of vulvar involvement were associated with symptom severity. Both the delay in diagnosis and the inappropriate previous treatments seem to indicate frequent misdiagnosis.
-
tacrolimus 0 1 ointment is it really effective in plasma cell Vulvitis report of four cases
Dermatology, 2008Co-Authors: Annarosa Virgili, Lucia Mantovani, Maria Michela Lauriola, Andrea Marzola, Monica CorazzaAbstract:Background: Plasma cell Vulvitis is a clinically and histologically well-characterized chronic disease that usually relapses after various topical therapies. Considering the inflamm
-
contact Vulvitis due to pseudowintera colorata in a topical herbal medicament
Acta Dermato-venereologica, 2007Co-Authors: Monica Corazza, Maria Michela Lauriola, Ferruccio Poli, Annarosa VirgiliAbstract:Sir, Besides traditional topical and systemic pharmacological treatments for the therapy of vulvovaginal yeast and bacterial infections, numerous over-the-counter medicaments containing natural substances (e.g. tea tree oil, echinacea, sodium caprylate, propolis) are marketed. Patients often prefer alternative medicine and selfprescribe herbal-based products. We report here an unusual case of acute Vulvitis that occurred in a young patient after prolonged topical use of an antifungal herbal preparation.
-
retrospective histopathologic reevaluation of 18 cases of plasma cell Vulvitis
Journal of Reproductive Medicine, 2005Co-Authors: Annarosa Virgili, Arianna Levratti, Andrea Marzola, Monica CorazzaAbstract:OBJECTIVE To determine some common histologic features in a series of plasma cell Vulvitis (PCV) cases. STUDY DESIGN In a retrospective study, 18 histologic sections, previously obtained by vulvar biopsy in women diagnosed as having PCV, were critically reevaluated by the same pathologist. RESULTS We observed that plasma cells in the dermal infiltrate were frequently present in a high percentage. Hemosiderin deposition and epithelial atrophy were 2 other histologic parameters useful for the diagnosis of PCV. Lozenge-shaped keratinocytes were rarely observed. CONCLUSION In our series of PCV the percentage of plasma cells seemed to be the most important parameter when making the diagnosis. In particular, when this percentage was > or = 50% it was a sufficient histologic parameter for a diagnosis of PCV. When the percentage was 25-50%, hemosiderin deposition and epithelial atrophy were additional histologic features helpful in diagnosing PCV. Under 25% plasma cells was nonspecific and related to the mucosal site of involvement.
Annarosa Virgili - One of the best experts on this subject based on the ideXlab platform.
-
comparative study on topical immunomodulatory and anti inflammatory treatments for plasma cell Vulvitis long term efficacy and safety
Journal of The European Academy of Dermatology and Venereology, 2015Co-Authors: Annarosa Virgili, Sara Minghetti, Alessandro Borghi, Monica CorazzaAbstract:Background Evidence on the treatment of plasma cell Vulvitis (PCV) is scarce and comparative studies are lacking. Objective To assess and compare the effectiveness and safety, on a long-term basis, of three topical interventions for the treatment of PCV. Methods Retrospectively collected efficacy and safety data of a cohort of PCV patients treated with fusidic acid 2% and betamethasone valerate 0.1% cream fixed combination (FA/BM, 14 patients), clobetasol propionate 0.05% ointment (CP, six patients) and tacrolimus 0.1% ointment (TC, four patients) at different regimens between January 2000 and June 2013 were analysed. Treatment outcome was assessed according to Investigator Global Assessment (i) symptoms and (ii) signs, at 12, 24 and 52 weeks. Results After 12 weeks, 85% of all patients achieved satisfactory improvement in PCV-related symptoms and maintained the improvement across a 52-week observation period. About 45% achieved a satisfactory result in clinical signs after 12 weeks, without further improvement during the following 9 months. No statistical differences in response were found among treatment groups at 12, 24 and 52 weeks. All study treatments were significantly more effective in improving PCV symptoms rather than clinical signs. With regard to treatment tolerability, one patient (7.1%) in FA/BM group and one (25%) in TC group discontinued the treatment due to local side-effects. Conclusions CP, FA/BM and TC are effective and safe in treating PCV, inducing both a rapid improvement of the disease, notably of symptoms, and stabilizing its control.
-
symptoms in plasma cell Vulvitis first observational cohort study on type frequency and severity
Dermatology, 2015Co-Authors: Annarosa Virgili, Monica Corazza, Sara Minghetti, Alessandro BorghiAbstract:Background: Studies assessing symptoms of plasma cell Vulvitis (PCV) are lacking. Objectives: To assess the prevalence and severity of PCV-related symptoms and identify possible associations between patient characteristics, clinical features of PCV and treatments administered before a definitive diagnosis. Methods: Thirty-six patients affected with PCV were included. Data were collected by direct interview and clinical examination. Results: Thirty patients (83.3%) complained of symptoms: burning was the most frequent (80.6%) while dyspareunia was the severest. Of the symptomatic patients, 73.3% experienced severe symptoms. Severity of symptoms was not associated with age at onset and duration of PCV. Almost 70% of the patients had previously undergone treatments. Conclusions: Symptoms in PCV are frequent and more than often severe. Neither age at onset nor duration of the disease nor the extent of vulvar involvement were associated with symptom severity. Both the delay in diagnosis and the inappropriate previous treatments seem to indicate frequent misdiagnosis.
-
tacrolimus 0 1 ointment is it really effective in plasma cell Vulvitis report of four cases
Dermatology, 2008Co-Authors: Annarosa Virgili, Lucia Mantovani, Maria Michela Lauriola, Andrea Marzola, Monica CorazzaAbstract:Background: Plasma cell Vulvitis is a clinically and histologically well-characterized chronic disease that usually relapses after various topical therapies. Considering the inflamm
-
contact Vulvitis due to pseudowintera colorata in a topical herbal medicament
Acta Dermato-venereologica, 2007Co-Authors: Monica Corazza, Maria Michela Lauriola, Ferruccio Poli, Annarosa VirgiliAbstract:Sir, Besides traditional topical and systemic pharmacological treatments for the therapy of vulvovaginal yeast and bacterial infections, numerous over-the-counter medicaments containing natural substances (e.g. tea tree oil, echinacea, sodium caprylate, propolis) are marketed. Patients often prefer alternative medicine and selfprescribe herbal-based products. We report here an unusual case of acute Vulvitis that occurred in a young patient after prolonged topical use of an antifungal herbal preparation.
-
retrospective histopathologic reevaluation of 18 cases of plasma cell Vulvitis
Journal of Reproductive Medicine, 2005Co-Authors: Annarosa Virgili, Arianna Levratti, Andrea Marzola, Monica CorazzaAbstract:OBJECTIVE To determine some common histologic features in a series of plasma cell Vulvitis (PCV) cases. STUDY DESIGN In a retrospective study, 18 histologic sections, previously obtained by vulvar biopsy in women diagnosed as having PCV, were critically reevaluated by the same pathologist. RESULTS We observed that plasma cells in the dermal infiltrate were frequently present in a high percentage. Hemosiderin deposition and epithelial atrophy were 2 other histologic parameters useful for the diagnosis of PCV. Lozenge-shaped keratinocytes were rarely observed. CONCLUSION In our series of PCV the percentage of plasma cells seemed to be the most important parameter when making the diagnosis. In particular, when this percentage was > or = 50% it was a sufficient histologic parameter for a diagnosis of PCV. When the percentage was 25-50%, hemosiderin deposition and epithelial atrophy were additional histologic features helpful in diagnosing PCV. Under 25% plasma cells was nonspecific and related to the mucosal site of involvement.
Andrew T Goldstein - One of the best experts on this subject based on the ideXlab platform.
-
plasma cell Vulvitis a systematic review
Journal of Lower Genital Tract Disease, 2021Co-Authors: Jill M Krapf, Kathryn Cavallo, Monica Saleeb, Andrew T GoldsteinAbstract:OBJECTIVE This systematic review aimed to present the available literature on plasma cell Vulvitis (PCV), a relatively uncommon form of inflammatory vulvovaginal dermatitis. MATERIALS AND METHODS A literature search was performed in PubMed, Science Direct, and Google Scholar using the following key words: "plasma cell Vulvitis," "Zoon Vulvitis," and "Vulvitis circumscripta plasmacellularis." Specific variables were assessed in each article, including patient age, menopausal status, comorbidities, presenting symptoms, symptom duration, histological description, treatment, and treatment response. RESULTS Thirty-nine articles met inclusion criteria, including 38 case reports and 1 observational study, with a total of 96 cases of PCV reported. The mean age of diagnosis was 52.9 years, with an age range of 8-76 years. Most common presenting symptoms included pruritis and vaginal discomfort, with average duration of symptoms 28.2 months (range = 2 months to 10 years). All reports demonstrated subepithelial plasma cell infiltrate on histology. Five percent of PCV cases reported concomitant autoimmune conditions and 6% sexually transmitted infections. Most common treatment modalities included topical corticosteroids (n = 41), tacrolimus (n = 6), and imiquimod (n = 6). In 53 reported outcomes, 88.7% of patients had resolution of symptoms with treatment. CONCLUSIONS Clinical research is needed to better determine the diagnostic criteria and to assess the efficacy of treatment options for PCV.
